Dendritic Cell Vaccination Strategy for the Treatment of Acute Myeloid Leukemia: A Systematic Review
Jamal Motallebzadeh Khanmiri,Mohsen Alizadeh,Sina Esmaeili,Zeinab Gholami,Ali Safarzadeh,Mohammad Khani-Eshratabadi,Amir Baghbanzadeh,Nazila Alizadeh,Behzad Baradaran,Mohammad Khani Eshrat Abadi
DOI: https://doi.org/10.1016/j.jcyt.2024.02.009
IF: 6.196
2024-02-01
Cytotherapy
Abstract:BACKGROUND AIMS: Acute myeloid leukemia (AML) is classified as a hematologic malignancy characterized by the proliferation of immature blood cells within the bone marrow (BM), resulting in an aberrant and unregulated cellular growth. The primary therapeutic modalities for AML include chemotherapy and hematopoietic stem cell transplantation. However, it is important to note that these treatments are accompanied by important adverse effects and mortality rates. Therefore, the need for more effective treatment options seems necessary, and dendritic cell (DC) vaccine therapy can be one of these options. In this study, we aim to investigate the effectiveness of DC vaccination therapy for the management of AML.METHODS: PubMed, Scopus, ProQuest, Web of Science, and Google Scholar databases were searched for this systematic review. The articles were evaluated based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, the articles related to the topic of this review were obtained in full text. The complete remission and partial remission, survival, correlative immune assays, and health-related metrics were used to evaluate this cellular immunotherapy effectiveness. The quality of the studies was assessed independently using the Cochrane risk-of-bias tools. The compiled data were input into a standard Excel spreadsheet. Each domain was evaluated as having either a "low risk," "high risk," or "unclear risk" of bias.RESULTS: Among the 3986 studies that were determined, a total of 11 correlated trials were selected for inclusion in this systematic review. DC vaccine therapy was effective in inducing complete and partial remission, and stabilization of the disease. Additionally, it was discovered that the treatment strengthened the immune system as seen by increased levels of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, Th1 cytokines, WT1-specific T cells, and activated NK cells.CONCLUSION: We conducted a systematic review that supports the use of DC vaccine therapy as an effective treatment for AML. The therapy demonstrated potentials in achieving remission, enhancing the immune system function, and increasing overall survival. However, more studies are required to improve the methods of preparing and delivering the DC vaccine, and to confirm its long-term safety and effectiveness.
cell biology,medicine, research & experimental,hematology,biotechnology & applied microbiology,cell & tissue engineering